Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
191
¥ millionWording
Definitive
How definitive the wording is.Recognition of Gain on Sale of Investment Securities (Extraordinary Income)
Subject Entity
WAKAMOTO PHARMACEUTICAL CO.,LTD. (filing company)
Target Locations / Products
上場有価証券１銘柄
Occurrence2024年3月8日
（投資有価証券売却益の発生時期）
This disclosure03/08/2024
Cause
コーポレートガバナンス・コードに基づく政策保有株式の見直しにより、資産効率の向上を図るため
Amount of Impact on Business Performance
191百万円（投資有価証券売却益、特別利益）
Accounting period in which recognized
Fiscal year ended March 2024
Impact on Earnings Forecast
当期純利益が予想を上回るため、本日通期業績予想の修正を開示
Outlook
2024年3月期に投資有価証券売却益191百万円を特別利益として計上する。本日、通期業績予想の修正を開示する。
| Item | Details |
|---|---|
| Event name | Recognition of Gain on Sale of Investment Securities (Extraordinary Income) |
| Date of occurrence | 2024年3月8日（投資有価証券売却益の発生時期） |
| Subject Entity | WAKAMOTO PHARMACEUTICAL CO.,LTD. (filing company) |
| Target Locations / Products | 上場有価証券１銘柄 |
| Cause | コーポレートガバナンス・コードに基づく政策保有株式の見直しにより、資産効率の向上を図るため |
| Amount of Impact on Business Performance | 191百万円（投資有価証券売却益、特別利益） |
| Accounting period in which recognized | Fiscal year ended March 2024 |
| Impact on Earnings Forecast | 当期純利益が予想を上回るため、本日通期業績予想の修正を開示 |
| Outlook | 2024年3月期に投資有価証券売却益191百万円を特別利益として計上する。本日、通期業績予想の修正を開示する。 |
Items this document does not state (16)
Date recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.コーポレートガバナンス・コードに基づき政策保有株式を見直し、資産効率を向上させるため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.